ReviewBlood2023
Causes and consequences of clonal hematopoiesis.
Review in Blood, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07675967 (Clonal Hematopoiesis Chemotherapy and Radiation Effects Study), which is not on this map. Cited by 121 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
Who cites it
121 citing papers in PubMed, 1 synthesis or guideline pooled it, 124 citations in OpenAlex.
- Effects of donor-engrafted clonal hematopoiesis in allogeneic and autologous stem cell transplantation: a systematic review and meta-analysis.Bone marrow transplantation · 2024Pooled it
- The effect of clonal hematopoiesis on long-term outcomes in patients undergoing coronary artery bypass grafting.BMC medicine · 2025Trial
- Association between JAK2 mutations and thoracic aortic aneurysms in myeloproliferative neoplasms.Journal of thrombosis and thrombolysis · 2026Review
- Clonal Hematopoiesis and CAR T Cell Therapy: From Biological Crosstalk to Clinical Implications.International journal of laboratory hematology · 2026Review
- Clinical Impact and Dynamics of Clonal Hematopoiesis withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Derivation of a blood count-based machine learning model to prioritise sequencing for high-risk clonal haematopoiesis: a retrospective cohort study.EClinicalMedicine · 2026Article
- Cardio-Oncological Sequelae of Autologous Stem Cell Transplantation: Role of Clonal Hematopoiesis in Cardiovascular Risk.JACC. Advances · 2026Article
- Finding clonal hematopoiesis before sequencing.Blood advances · 2026Article
- Clonal Dynamics After Allogeneic Hematopoietic Stem Cell Transplantation from Related Donors: A Case Series.International journal of molecular sciences · 2026Article
- P-selectin delineates conserved functional heterogeneity in early hematopoietic stem cell aging in humans and mice.The EMBO journal · 2026Article
- Histiocytosis development and clinical variation through the lens of genomics.The Journal of pathology · 2026Review
- Risk factors of clonal hematopoiesis of indeterminate potential.Clinical medicine (London, England) · 2026Article
- Genetic influences on haematopoiesis.Nature reviews. Genetics · 2026Review
- Clonal Hematopoiesis in Colorectal Cancer: Mechanisms and Implications.Cancer medicine · 2026Review
- Mosaic chromosomal alterations are suppressed in older adults with HIV.Communications biology · 2026Article
- Evolution of clonal hematopoiesis during cancer treatment and its impact on outcomes.The Journal of clinical investigation · 2026Article
- Shared mechanisms of organ fibrosis.JCI insight · 2026Review
- Context-dependent selection sculpts mutational landscapes in the normal lung.Research square · 2026Article
- Drivers of Inflammation; Clonal Hematopoiesis: Clinical Implications.Balkan medical journal · 2026Article
- Insulin Resistance as a Systemic Metabolic Risk State for Cancer: Mechanisms, Biomarkers, and Prevention.International journal of molecular sciences · 2026Review
61 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
abstractClonal hematopoiesis (CH) is described as the outsized contribution of expanded clones of hematopoietic stem and progenitor cells (HSPCs) to blood cell production. The prevalence of CH increases dramatically with age. CH can be caused by somatic mutations in individual genes or by gains and/or losses of larger chromosomal segments. CH is a premalignant state; the somatic mutations detected in CH are the initiating mutations for hematologic malignancies, and CH is a strong predictor of the development of blood cancers. Moreover, CH is associated with nonmalignant disorders and increased overall mortality. The somatic mutations that drive clonal expansion of HSPCs can alter the function of terminally differentiated blood cells, including the release of elevated levels of inflammatory cytokines. These cytokines may then contribute to a broad range of inflammatory disorders that increase in prevalence with age. Specific somatic mutations in the peripheral blood in coordination with blood count parameters can powerfully predict the development of hematologic malignancies and overall mortality in CH. In this review, we summarize the current understanding of CH nosology and origins. We provide an overview of available tools for risk stratification and discuss management strategies for patients with CH presenting to hematology clinics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.